Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Core Insights - Viridian Therapeutics, Inc. has completed enrollment in its phase 3 clinical trials REVEAL-1 and REVEAL-2 for VRDN-003, targeting patients with active and chronic Thyroid Eye Disease (TED) respectively [1] Company Overview - Viridian Therapeutics is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases [1] Product Details - VRDN-003 is a subcutaneously delivered, half-life extended monoclonal antibody that targets the insulin-like growth factor [1]